China pharma M&A heats up with Luye deal

Luye Pharma Group has agreed to buy a subsidiary of Swiss counterpart Acino, becoming the latest Chinese healthcare company to look overseas for expansion.

China pharma M&A heats up with Luye deal

Luye Pharma Group has agreed to buy a subsidiary of Swiss counterpart Acino, becoming the latest Chinese healthcare company to look overseas for expansion.

Luye Pharma, backed by Singapore’s sovereign wealth fund GIC, is buying a branch of Acino that makes transdermal drug delivery systems TDS, or patches. The 245 million $270 million acquisition means Luye is about to control one of the largest TDS manufacturers in Europe.

...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition

EVENTS